DHEA-S Test: When to Order It, What the Results Mean, and What to Do Next

What Is DHEA-S and Why Does It Matter for Women?

DHEA-S (dehydroepiandrosterone sulfate) is the sulfated, storage form of DHEA. Your adrenal cortex makes it in large quantities; the ovaries and peripheral tissues contribute a small fraction. Because DHEA-S has a half-life of 7 to 10 hours compared to DHEA's 15 to 30 minutes, it is the more clinically reliable marker of adrenal androgen output.

For women, this matters on two levels. First, DHEA-S serves as a precursor to both estrogens and androgens in peripheral tissues, which means its level is woven into your experience of acne, libido, body composition, and bone density across your whole reproductive life. Second, abnormally high or low values can point to conditions ranging from PCOS to adrenal tumors to autoimmune adrenal destruction, all of which disproportionately affect women.

How DHEA-S Differs from DHEA and Total Testosterone

Clinicians sometimes order DHEA, DHEA-S, and testosterone together, but they are not interchangeable. DHEA-S reflects primarily adrenal androgen production, while total testosterone reflects both ovarian and adrenal output plus peripheral conversion. If testosterone is high but DHEA-S is normal, the source is likely ovarian. If both are elevated, or if DHEA-S is very high (above 700 µg/dL in a non-pregnant woman), adrenal pathology moves to the top of the differential.

The Adrenarche-to-Adrenopause Arc

DHEA-S production follows a predictable arc across a woman's life:

• Adrenarche (ages 6-8): The adrenal cortex begins secreting DHEA-S for the first time, driving early pubic hair growth.
• Peak (ages 20-30): Mean serum DHEA-S in women is roughly 200-250 µg/dL.
• Decline: Output falls approximately 2% per year after peak, so by age 70 a woman may have only 10-20% of her young-adult value.
• Adrenopause: The term used for the age-related decline; there is no abrupt event analogous to menopause, but the trajectory is consistent.

Understanding this arc prevents misdiagnosis. A 65-year-old woman with a DHEA-S of 55 µg/dL is almost certainly experiencing normal adrenopause, not adrenal insufficiency.

Normal DHEA-S Ranges Across a Woman's Life

Reference ranges differ by assay and laboratory, so always interpret your result against the range printed on your own report. The table below uses commonly cited approximate values as orientation, not absolute cutoffs.

| Life Stage | Approximate DHEA-S Range (µg/dL) | |---|---| | Girls, pre-adrenarche (<6 years) | <15 | | Girls, adrenarche (6-9 years) | 15-85 | | Reproductive-age women (18-30) | 45-380 | | Reproductive-age women (31-45) | 35-280 | | Perimenopause (approx. 46-55) | 20-230 | | Post-menopause | 10-150 | | Pregnancy (any trimester) | Lower than non-pregnant norms |

The Endocrine Society's clinical practice guideline on adrenal incidentalomas uses a threshold of 700 µg/dL as the upper boundary that prompts urgent workup for adrenocortical carcinoma in adults. Values between the upper end of normal and 700 µg/dL still warrant evaluation, particularly if the rise is rapid or accompanied by virilizing features.

When Should a Woman Order a DHEA-S Test?

DHEA-S is not a routine screening test. Order it when there is a specific clinical question you are trying to answer. The following situations are the most common indications in women.

Signs of Androgen Excess

Hirsutism, acne in adult women, androgenic alopecia (female-pattern hair loss), and clitoromegaly all raise the question of where excess androgens are coming from. A DHEA-S level helps distinguish adrenal from ovarian sources. ACOG Practice Bulletin 194 on polycystic ovary syndrome recommends checking DHEA-S as part of the biochemical androgen panel when clinical features of hyperandrogenism are present, to exclude non-classic congenital adrenal hyperplasia (NCCAH) and adrenal tumors.

A DHEA-S above 700 µg/dL in a woman of any reproductive age should trigger imaging of the adrenal glands without waiting for other test results.

PCOS Evaluation

Women with PCOS have mildly elevated DHEA-S in roughly 25-30% of cases, reflecting increased adrenal androgen secretion alongside ovarian androgen excess. This subgroup, sometimes called adrenal PCOS, may respond differently to treatment. Knowing your DHEA-S level at diagnosis helps your clinician decide whether to target ovarian suppression (hormonal contraception, spironolactone) or whether adrenal-specific interventions deserve consideration.

Premature Ovarian Insufficiency and Adrenal Autoimmunity

Approximately 4% of women with premature ovarian insufficiency (POI) have coexisting autoimmune adrenal insufficiency (Addison disease). ASRM guidelines recommend adrenal antibody testing (21-hydroxylase antibodies) in women with POI, and a low DHEA-S supports further workup for primary adrenal insufficiency. Missing Addison disease in a woman with POI is a serious safety error because adrenal crisis can be life-threatening.

Unexplained Fatigue, Low Libido, or Mood Changes in Perimenopause and Menopause

Ovarian estrogen and androgen production both decline in the menopausal transition. The adrenal glands become a more important source of androgens after menopause, but adrenal output is also declining. Some menopausal women with symptoms of low libido, fatigue, or depressed mood have measurably low DHEA-S values, though the correlation between DHEA-S levels and symptom severity is modest at best. The evidence for supplementing DHEA to treat these symptoms is discussed below.

Adrenal Insufficiency Workup

In a woman with unexplained fatigue, salt craving, hypotension, hyperpigmentation, or weight loss, DHEA-S is one of several markers used to assess adrenal cortical reserve. A very low DHEA-S (well below the lower limit of the age-adjusted reference range) combined with low or borderline cortisol, hyponatremia, and hyperkalemia points toward primary adrenal insufficiency. Cortisol stimulation testing (cosyntropin stimulation test) is the definitive test, but DHEA-S adds complementary information about the zona reticularis specifically.

Suspected Congenital Adrenal Hyperplasia

Non-classic 21-hydroxylase deficiency (NCCAH) is the most common autosomal recessive disorder of steroidogenesis, affecting roughly 1 in 100 to 1 in 1,000 women depending on ancestry. It presents in adolescence or adulthood with hirsutism, irregular cycles, and sometimes infertility, overlapping significantly with PCOS. DHEA-S may be normal or mildly elevated in NCCAH; the distinguishing test is a morning 17-hydroxyprogesterone (17-OHP). Order both when NCCAH is on the differential.

Adrenal Incidentaloma and Adrenocortical Carcinoma Screening

When an adrenal mass is found incidentally on imaging, DHEA-S is part of the hormonal workup. The Endocrine Society guideline notes that a markedly elevated DHEA-S in this context suggests adrenocortical carcinoma (ACC) and warrants urgent surgical referral. ACC has a female-to-male incidence ratio of approximately 1.5:1, making it relatively more common in women.

What High DHEA-S Means in Women

High DHEA-S most commonly indicates one of the following:

• PCOS with adrenal involvement (mild to moderate elevation, usually 350-500 µg/dL)
• Functional adrenal hyperandrogenism (not associated with a tumor but with dysregulation of adrenal androgen secretion)
• NCCAH (mild to moderate elevation alongside elevated 17-OHP)
• Adrenocortical adenoma or carcinoma (often above 500-700 µg/dL; carcinoma frequently above 700 µg/dL)
• Cushing syndrome (may have elevated DHEA-S but often normal or low depending on etiology)
• Exogenous DHEA supplementation (over-the-counter supplements can push levels well above the normal range)

What Symptoms Point to High DHEA-S?

You may notice new or worsening:

• Chin, chest, or abdominal hair growth (hirsutism)
• Cystic acne along the jaw or back
• Temporal hair thinning or recession
• Irregular or absent periods
• Clitoral enlargement (in severe or rapid-onset cases, suggesting a tumor)
• Deepening of the voice (again, suggests rapid-onset virilization from a tumor)

Rapid progression of virilizing symptoms over weeks to months demands urgent imaging. Gradual onset over years is more typical of PCOS or functional hyperandrogenism.

What Low DHEA-S Means in Women

Low DHEA-S in the context of normal aging is expected. Low DHEA-S that falls below the age-adjusted reference range, especially in a younger woman, may indicate:

• Primary adrenal insufficiency (Addison disease): Autoimmune destruction of the adrenal cortex reduces output of cortisol, aldosterone, and adrenal androgens simultaneously.
• Secondary or tertiary adrenal insufficiency: Pituitary or hypothalamic dysfunction suppresses ACTH, which in turn lowers adrenal androgen output. Causes include long-term glucocorticoid use (the most common cause), pituitary tumors, Sheehan syndrome (pituitary infarction after postpartum hemorrhage), or hypopituitarism from any cause.
• Chronic illness or critical illness: DHEA-S falls nonspecifically in severe systemic disease, HIV infection, anorexia nervosa, and rheumatoid arthritis.
• Glucocorticoid therapy: Prednisone or equivalent suppresses ACTH and secondarily lowers DHEA-S. This is expected pharmacologically, not a sign of separate adrenal pathology.

A practical framework for low DHEA-S interpretation: if DHEA-S is low and the woman has symptoms (fatigue, hypotension, nausea, salt craving), perform a cosyntropin stimulation test and check morning cortisol before assuming the finding is incidental. If DHEA-S is low and the woman is asymptomatic and postmenopausal, the finding is very likely physiologic adrenopause.

How the Menstrual Cycle, Pregnancy, and Menopause Change DHEA-S

Across the Menstrual Cycle

DHEA-S is not acutely regulated by LH or FSH, so it does not spike at ovulation the way estradiol or LH do. Levels are stable enough across the cycle that you can draw the test on any day. This makes DHEA-S one of the more practical androgen markers, because testosterone and free testosterone do fluctuate across the cycle and with time of day.

During Pregnancy

DHEA-S drops substantially in pregnancy. The placenta converts maternal DHEA-S into estrogens, particularly estriol, which lowers circulating DHEA-S concentrations. By the third trimester, DHEA-S levels may be 50-60% lower than pre-pregnancy values. Never apply non-pregnant reference ranges to a pregnant woman's DHEA-S result. A value of 80 µg/dL is unremarkable in late pregnancy but would be low-normal in a reproductive-age woman outside pregnancy.

In Perimenopause and Postmenopause

Ovarian estrogen and androgen production decline sharply in perimenopause and essentially cease after menopause. The adrenal contribution to total androgen production becomes proportionally more important, even though adrenal output itself is also declining. Women in their 50s and 60s often ask whether low DHEA-S explains their fatigue, low libido, or vaginal dryness. The honest answer is: DHEA-S correlates imperfectly with these symptoms. A structured evaluation (including estradiol, FSH, thyroid function, iron studies, and sleep assessment) is more informative than treating a DHEA-S number in isolation.

Pregnancy and Lactation: Special Considerations

DHEA-S is not a drug, so there is no pregnancy category or lactation transfer risk in the pharmacological sense. The considerations here involve two different scenarios.

Testing During Pregnancy

If you need to evaluate androgen excess during pregnancy (for example, a new adrenal mass is found or severe hirsutism develops), standard DHEA-S reference ranges do not apply. Consult with a maternal-fetal medicine specialist or reproductive endocrinologist who can interpret the result in the context of gestational age and placental steroidogenesis.

DHEA Supplementation During Pregnancy and Breastfeeding

Some fertility clinics use DHEA supplementation as an adjunct for poor ovarian responders undergoing IVF. A 2018 meta-analysis in Fertility and Sterility found a modest improvement in live birth rates in women with diminished ovarian reserve who used DHEA supplementation before IVF, though the evidence base remains limited. DHEA supplementation must be stopped once pregnancy is confirmed. There are no adequate human studies of DHEA in pregnancy, and androgen exposure during organogenesis carries theoretical risk of virilization of a female fetus. DHEA is also not recommended during breastfeeding because its transfer into breast milk is unknown and neonatal androgen exposure could be harmful.

Any woman considering DHEA supplementation for fertility should work with a reproductive endocrinologist, not purchase supplements independently, and must use effective contraception until a monitored IVF cycle begins.

How to Lower High DHEA-S

Treatment depends entirely on the cause.

For PCOS-Related Adrenal Hyperandrogenism

Combined oral contraceptives (COCs) suppress both ovarian and adrenal androgen production by lowering ACTH pulsatility and increasing sex hormone-binding globulin (SHBG). In women with PCOS, COCs reduce DHEA-S by roughly 20-40%. Spironolactone at 50-200 mg/day blocks androgen receptors and reduces hirsutism but does not meaningfully lower DHEA-S production itself.

Metformin, widely used in PCOS for insulin sensitization, has a less consistent effect on DHEA-S specifically, though it can reduce total androgen levels when hyperinsulinemia is a driver.

For Adrenal Tumors

Surgical resection is the treatment for adrenocortical adenoma or carcinoma. Mitotane is used as adjuvant therapy for ACC. These decisions belong with an endocrinologist and a surgical oncologist.

For NCCAH

Low-dose glucocorticoids (hydrocortisone or prednisone) suppress excess adrenal androgen production in symptomatic NCCAH. This approach requires careful monitoring because excessive glucocorticoid exposure causes its own set of problems, particularly bone loss and adrenal suppression.

How to Raise Low DHEA-S

Physiologic Adrenopause: Watch and Wait

Low DHEA-S that falls within the expected range for a woman's age does not need treatment. No major professional guideline, including those from the Endocrine Society or The Menopause Society (formerly NAMS), recommends routine DHEA-S replacement for aging women.

Adrenal Insufficiency

Women with confirmed adrenal insufficiency (primary or secondary) are prescribed glucocorticoid replacement (hydrocortisone, typically 15-25 mg/day in divided doses, or equivalent) and, in primary adrenal insufficiency, mineralocorticoid replacement with fludrocortisone. Some clinicians add DHEA replacement at 25-50 mg/day in women with primary adrenal insufficiency who have ongoing fatigue and low libido despite adequate cortisol and aldosterone replacement. The Endocrine Society gives this a weak recommendation because the trial data show modest benefit on mood and sexual function but inconsistent effects on other outcomes.

Intravaginal Prasterone (DHEA) for GSM

Prasterone (Intrarosa), an intravaginal insert containing 6.5 mg DHEA, is FDA-approved for dyspareunia due to genitourinary syndrome of menopause (GSM). FDA approval was granted in 2016 based on trials showing reduced vaginal dryness and pain with intercourse, with minimal systemic absorption. Serum DHEA-S rises slightly but stays within the normal postmenopausal range. This is a targeted treatment for a specific symptom, not a general "hormone optimization" strategy.

Oral DHEA Supplements

Over-the-counter DHEA supplements (typically 25-100 mg) are sold as dietary supplements in the US without prescription. They can raise DHEA-S levels, but the clinical benefit for unselected perimenopausal or postmenopausal women is not established. A 2006 randomized trial published in NEJM found no significant benefit of oral DHEA at 50 mg/day on body composition, muscle strength, or quality of life in healthy older adults. Women who take over-the-counter DHEA without monitoring can inadvertently push their DHEA-S into supraphysiologic ranges, increasing the risk of acne, hair loss, and, theoretically, androgen-sensitive tumor promotion.

Who Should Get a DHEA-S Test (and Who Probably Should Not)

Order DHEA-S if you:

• Have new or worsening hirsutism, jaw or back acne, or temporal hair loss
• Are being evaluated for PCOS and your clinician needs to characterize androgen source
• Have irregular periods and your clinician is ruling out NCCAH alongside PCOS
• Have been diagnosed with an adrenal incidentaloma and need hormonal secretion workup
• Have POI and your clinician is screening for coexisting autoimmune adrenal insufficiency
• Have known or suspected hypopituitarism or primary adrenal insufficiency
• Are experiencing rapid virilization (new facial hair, voice changes, clitoral enlargement) and need urgent evaluation

Do not order DHEA-S as a routine wellness screen if you:

• Have no symptoms or clinical indication
• Are postmenopausal with only fatigue and low libido and want to "check your hormones" (a complete panel including thyroid, iron studies, estradiol, and FSH is more informative)
• Are pregnant (unless under specialist guidance with pregnancy-specific reference ranges)
• Are already on DHEA supplementation and have not stopped it before the draw (supplements must be held for at least 2 weeks before testing to reflect endogenous production)

Practical Testing Tips

Timing: Morning draw (8-10 AM) is preferred, not because DHEA-S has strong diurnal variation, but because cortisol does, and the two are often ordered together.

Cycle day: Any day of the menstrual cycle is acceptable.

Hold supplements: Stop OTC DHEA for at least 2 weeks before the test to get a meaningful baseline.

Pair with: Depending on the clinical question, consider ordering total testosterone, free testosterone, LH, FSH, prolactin, 17-OHP (morning, early follicular phase), fasting insulin, and glucose if PCOS is the question. For adrenal insufficiency, add morning cortisol, ACTH, sodium, and potassium.

Reference range: Always check which assay your laboratory uses. Immunoassay and LC-MS/MS (liquid chromatography-tandem mass spectrometry) methods can give different absolute values. LC-MS/MS is the reference method with better precision at low concentrations, which matters most in postmenopausal women.